{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:36:34Z","timestamp":1788431794934,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Monoclonal antibodies targeting the CGRP pathway are effective and safe for prophylactic treatment of episodic (EM) and chronic migraine (CM). In case of treatment failure of a CGRP pathway targeting\u00a0mAb, physician has to decide whether using another anti-CGRP pathway\u00a0mAb is useful. This interim analysis of\u00a0Finesse\u00a0Study evaluates effectiveness of the anti-CGRP\u00a0mAb fremanezumab in patients with a history of other prior anti-CGRP pathway mAb treatments (switch patients).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p><jats:sc>Finesse<\/jats:sc>, a non-interventional, prospective, multicentre, two-country (Germany-Austria) study observing migraine patients receiving fremanezumab in clinical routine. This subgroup analysis presents data on documented effectiveness over 3\u00a0months after the first dose of fremanezumab in switch patients. Effectiveness was evaluated based on reduction in average number of migraine days per month (MMDs), MIDAS and HIT-6 scores changes as well as in number of monthly days with acute migraine medication use.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One hundred fifty-three out of 867 patients with a history of anti-CGRP pathway\u00a0mAb treatment prior to initiation of fremanezumab were analysed. Switch to fremanezumab led to\u2009\u2265\u200950% MMD reduction in 42.8% of migraine patients, with higher response rate in EM (48.0%) than in CM patients (36.5%). A\u2009\u2265\u200930% MMD reduction was achieved by 58.7% in CM patients. After three months, monthly number of migraine days decreased by 6.4\u2009\u00b1\u20095.87 (baseline: 13.6\u2009\u00b1\u20096.5; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) in all patients, 5.2\u2009\u00b1\u20094.04 in EM and 7.7\u2009\u00b1\u20097.45 in CM patients. MIDAS scores decreased from 73.3\u2009\u00b1\u200956.8 (baseline) to 50.3\u2009\u00b1\u200952.9 (after 3\u00a0months; <jats:italic>p<\/jats:italic>\u2009=\u20090.0014), HIT-6 scores decreased from 65.9\u2009\u00b1\u20095.0 to 60.9\u2009\u00b1\u20097.2 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). Concomitant use of acute migraine medication had decreased from 9.7\u2009\u00b1\u20094.98\u00a0(baseline) to 4.9\u2009\u00b1\u20093.66\u00a0(3\u00a0months) (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our results show that about 42.8% of anti-CGRP pathway\u00a0mAb-non-responder benefit from switching to fremanezumab. These results suggest that switching to fremanezumab may be a promising option for patients experiencing poor tolerability or inadequate efficacy with prior other anti-CGRP pathway mAb use.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:sc>Finesse<\/jats:sc>\u00a0Study is registered on the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (EUPAS44606).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s10194-023-01593-2","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T15:05:06Z","timestamp":1684854306000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Real-world effectiveness of fremanezumab in patients with migraine switching from\u00a0another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study"],"prefix":"10.1186","volume":"24","author":[{"given":"Andreas","family":"Straube","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Broessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charly","family":"Gaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xenia","family":"Hamann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Hipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Kraya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Neeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"key":"1593_CR1","volume-title":"Clinical Neurology","author":"RP Simon","year":"2009","unstructured":"Simon RP, Aminoff MJ, Greenberg DA (2009) Clinical Neurology, 7th edn. McGraw-Hill Professional Publishing, New York, USA, A Lange medical book","edition":"7"},{"key":"1593_CR2","unstructured":"World Health Organization (2012) Headache disorders Fact Sheet N\u00b0277, Geneva; https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/headache-disorders. (retrieved 01.25.2023)"},{"key":"1593_CR3","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S0140-6736(04)15440-8","volume":"363","author":"SD Silberstein","year":"2004","unstructured":"Silberstein SD (2004) Migraine. The Lancet 363:381\u2013391. https:\/\/doi.org\/10.1016\/S0140-6736(04)15440-8","journal-title":"The Lancet"},{"key":"1593_CR4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/304129a0","volume":"304","author":"MG Rosenfeld","year":"1983","unstructured":"Rosenfeld MG, Mermod JJ, Amara SG, Swanson LW, Sawchenko PE, Rivier J, Vale WW, Evans RM (1983) Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature 304:129\u2013135. https:\/\/doi.org\/10.1038\/304129a0","journal-title":"Nature"},{"key":"1593_CR5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/ana.410330109","volume":"33","author":"PJ Goadsby","year":"1993","unstructured":"Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33:48\u201356. https:\/\/doi.org\/10.1002\/ana.410330109","journal-title":"Ann Neurol"},{"issue":"Suppl 2","key":"1593_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/head.13081","volume":"57","author":"L Edvinsson","year":"2017","unstructured":"Edvinsson L (2017) The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache 57(Suppl 2):47\u201355. https:\/\/doi.org\/10.1111\/head.13081","journal-title":"Headache"},{"key":"1593_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2217\/pmt-2020-0030","volume":"11","author":"LM Frerichs","year":"2021","unstructured":"Frerichs LM, Friedman DI (2021) Galcanezumab for the prevention of migraine. Pain Manag 11:101\u2013112. https:\/\/doi.org\/10.2217\/pmt-2020-0030","journal-title":"Pain Manag"},{"key":"1593_CR8","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377:2113\u20132122. https:\/\/doi.org\/10.1056\/NEJMoa1709038","journal-title":"N Engl J Med"},{"key":"1593_CR9","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1111\/1440-1681.13700","volume":"49","author":"YMT, Hartoyo V, Hariyanto,","year":"2022","unstructured":"YMT, Hartoyo V, Hariyanto, (2022) Efficacy and safety of eptinezumab as preventive treatment for episodic\/chronic migraine: a systematic review and meta-analysis. Clin Exp Pharmacol Physiol 49:1156\u20131168. https:\/\/doi.org\/10.1111\/1440-1681.13700","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"1593_CR10","doi-asserted-by":"crossref","unstructured":"Zhu C, Guan J et al. (2019) Erenumab safety and efficacy in migraine: A systematic review and meta-analysis of randomized clinical trials. Medicine 98:e184883","DOI":"10.1097\/MD.0000000000018483"},{"key":"1593_CR11","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/WCO.0000000000000438","volume":"30","author":"DD Mitsikostas","year":"2017","unstructured":"Mitsikostas DD, Reuter U (2017) Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies. Curr Opin Neurol 30:272\u2013280. https:\/\/doi.org\/10.1097\/WCO.0000000000000438","journal-title":"Curr Opin Neurol"},{"key":"1593_CR12","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1177\/03331024211018137","volume":"41","author":"F Frank","year":"2021","unstructured":"Frank F, Ulmer H, Sidoroff V, Broessner G (2021) CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis. Cephalalgia 41:1222\u201339.\u00a0","journal-title":"Cephalalgia"},{"key":"1593_CR13","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s40263-021-00834-9","volume":"35","author":"LH Overeem","year":"2021","unstructured":"Overeem LH, Raffaelli B, Mecklenburg J, Kelderman T, Neeb L, Reuter U (2021) Indirect comparison of topiramate and monoclonal antibodies against CGRP or its receptor for the prophylaxis of episodic migraine: a systematic review with meta-analysis. CNS Drugs 35:805\u2013820. https:\/\/doi.org\/10.1007\/s40263-021-00834-9","journal-title":"CNS Drugs"},{"key":"1593_CR14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s10194-022-01498-6","volume":"23","author":"P Barbanti","year":"2022","unstructured":"Barbanti P, Egeo G, Aurillia C et al (2022) Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain 23:138. https:\/\/doi.org\/10.1186\/s10194-022-01498-6","journal-title":"J Headache Pain"},{"key":"1593_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0304-3959(00)00305-5","volume":"88","author":"WF Stewart","year":"2000","unstructured":"Stewart WF, Lipton RB, Kolodner KB et al (2000) Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain 88:41\u201352. https:\/\/doi.org\/10.1016\/S0304-3959(00)00305-5","journal-title":"Pain"},{"key":"1593_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/0333102410379890","volume":"31","author":"M Yang","year":"2011","unstructured":"Yang M, Rendas-Baum R, Varon SF et al. (2011) Validation of the Headache Impact Test (HIT-6\u2122) across episodic and chronic migraine. Cephalalgia 31:357\u201367.\u00a0","journal-title":"Cephalalgia"},{"key":"1593_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"J Olesen","year":"2018","unstructured":"Olesen J, (2018) Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders. Cephalalgia 38:1\u2013211.\u00a0","journal-title":"Cephalalgia"},{"key":"1593_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin F, Ashina M et al (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain 23:67. https:\/\/doi.org\/10.1186\/s10194-022-01431-x","journal-title":"J Headache Pain"},{"key":"1593_CR19","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1177\/0333102420983282","volume":"41","author":"M Bhakta","year":"2021","unstructured":"Bhakta M, Vuong T et al (2021) Migraine therapeutics differentially modulate the CGRP pathway. Cephalalgia 41:499\u2013514. https:\/\/doi.org\/10.1177\/0333102420983282","journal-title":"Cephalalgia"},{"key":"1593_CR20","doi-asserted-by":"publisher","first-page":"e2794","DOI":"10.1212\/WNL.0000000000010740","volume":"95","author":"C Ziegeler","year":"2020","unstructured":"Ziegeler C, Mehnert J et al (2020) Central effects of erenumab in migraine patients: an event-related functional imaging study. Neurology 95:e2794\u2013e2802. https:\/\/doi.org\/10.1212\/WNL.0000000000010740","journal-title":"Neurology"},{"key":"1593_CR21","doi-asserted-by":"publisher","first-page":"e77146","DOI":"10.7554\/eLife.77146","volume":"11","author":"H Basedau","year":"2022","unstructured":"Basedau H, Sturm LM et al. (2022) Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target - an fMRI study. Elife 11: e77146","journal-title":"Elife"},{"key":"1593_CR22","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/head.13729","volume":"60","author":"C Ziegeler","year":"2020","unstructured":"Ziegeler C, May A (2020) Non-responders to treatment with antibodies to the CGRP-receptor may profit from a switch of antibody class. Headache 60:469\u2013470. https:\/\/doi.org\/10.1111\/head.13729","journal-title":"Headache"},{"key":"1593_CR23","doi-asserted-by":"publisher","DOI":"10.1159\/000518899","author":"IP Ruiz","year":"2021","unstructured":"Ruiz IP, Ferr\u00e1ndez JS-R, Fonfr\u00eda AC et al (2021) Early experiences in switching between monoclonal antibodies in patients with nonresponsive migraine in Spain: a case series. Eur Neurol. https:\/\/doi.org\/10.1159\/000518899","journal-title":"Eur Neurol"},{"key":"1593_CR24","unstructured":"Robbins L et al. (2019) Pract Pain Manag. CGRP Monoclonal Antibodies for Chronic Migraine: Year 1 of Clinical Use. https:\/\/www.practicalpainmangement.com\/pain\/headache\/cgrp-monoclonal-antibodies-chronic-migraine-year-1-clinical-use"},{"key":"1593_CR25","doi-asserted-by":"publisher","unstructured":"Brice\u00f1o-Casado MdP (2021) Gil-Sierra MD, De-la-Calle_Riaguas B (2021) Switching of monoclonal antibodies against calcitonin gene-related peptide in chronic migraine in clinical practice: a case series. Eur J Hosp Pharm. 14:ejhpharm-2021-002946. https:\/\/doi.org\/10.1136\/ejhpharm-2021-002946","DOI":"10.1136\/ejhpharm-2021-002946"},{"key":"1593_CR26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/03331024211048765","volume":"42","author":"LH Overeem","year":"2021","unstructured":"Overeem LH, Peikert A, Hofacker MD et al (2021) Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study. Cephalalgia 42:291\u2013301. https:\/\/doi.org\/10.1177\/03331024211048765","journal-title":"Cephalalgia"},{"key":"1593_CR27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s10194-022-01415-x","volume":"23","author":"MT Driessen","year":"2022","unstructured":"Driessen MT, Cohen JM, Thompson SF et al (2022) Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine. J Headache Pain 23:56. https:\/\/doi.org\/10.1186\/s10194-022-01415-x","journal-title":"J Headache Pain"},{"key":"1593_CR28","doi-asserted-by":"publisher","unstructured":"Go\u00dfrau G, F\u00f6rderreuther S, Ruscheweyh R, Ruschil V, Sprenger T, Lewis D, et al. (2023) Konsensusstatement der Migr\u00e4ne- und Kopfschmerzgesellschaften (DMKG, \u00d6KSG & SKG) zur Therapiedauer der medikament\u00f6sen Migr\u00e4neprophylaxe [Consensus statement of the migraine and headache societies (DMKG, \u00d6KSG, and SKG) on the duration of pharmacological migraine prophylaxis]. Nervenarzt. 94(4):306-317. German. https:\/\/doi.org\/10.1007\/s00115-022-01403-1. Epub 2022 Oct 26. Erratum in: Nervenarzt. 2023 Jan 16;: PMID: 36287216; PMCID: PMC9607745","DOI":"10.1007\/s00115-022-01403-1"},{"key":"1593_CR29","doi-asserted-by":"crossref","unstructured":"Diener H.-C., F\u00f6rderreuther S, Kropp P. et al. (2022) Therapie der Migr\u00e4neattacke und Prophylaxe der Migr\u00e4ne, S1-Leitlinie, 2022, DGN und DMKG, in: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. https:\/\/doi.org\/leitlinie\/therapie-der-migraneattacke-und-prophylaxeder-migrane-2022","DOI":"10.1007\/s42451-023-00550-2"},{"key":"1593_CR30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s10194-021-01323-6","volume":"22","author":"A Scheffler","year":"2021","unstructured":"Scheffler A, Schenk H, Wurthmann S et al (2021) CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience. J Headache Pain 22:111. https:\/\/doi.org\/10.1186\/s10194-021-01323-6","journal-title":"J Headache Pain"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01593-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-023-01593-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01593-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T15:05:13Z","timestamp":1684854313000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01593-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1593"],"URL":"https:\/\/doi.org\/10.1186\/s10194-023-01593-2","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,23]]},"assertion":[{"value":"23 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prior to the inclusion of the first patient, the protocol and other relevant study documents were submitted to the responsible independent ethics committee in accordance with all applicable legislation and regulation. Due to the non-interventional nature of this study, patients were not exposed to any study-specific diagnostic or therapeutic measures; documented voluntary informed consent was a prerequisite for any study-related documentation of data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors give their consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have had or are having the following economic or personal ties to the pharmaceutical industry, consulting firms, payers, or healthcare providers: A. Straube is or was member of the following advisory boards: Novartis, Lilly, Sanofi, Allergan, TEVA, and speaker or member of speaker boards on behalf of Novartis, Lilly, Sanofi, Allergan, TEVA. He acted as consultant for Sanofi and TEVA, received grant support for research or education from Novartis and acted as an editorial board member for Lilly, Sanofi and Novartis. G. Broessner was or is member of the following advisory boards: Novartis, Lilly, TEVA, Gr\u00fcnenthal, and speaker or member of following speakers boards: Novartis, Lilly, TEVA, Gr\u00fcnenthal; Consultant: Novartis, Lilly, TEVA, Gr\u00fcnenthal; he received grant support for research or education from TEVA<b>.<\/b> C. Gaul is or was member of the following advisory Boards: Abbvie, Lilly, Novartis Pharma, Hormosan Pharma, Sanofi-Aventis, Perfood, and TEVA, and speaker or member of the following speaker boards: Abbvie, Lilly, Novartis Pharma, Hormosan Pharma, Gr\u00fcnenthal, Sanofi-Aventis, Reckitt-Benckiser and TEVA. He acted as consultant for Weber & Weber, Lundbeck, and Perfood, and served in the following editorial boards: Acta Neurologica Scandinavia, Frontiers in Neurology, and Medizinischer Sachverst\u00e4ndiger; Author royalties: Novartis Pharma; furthermore, he is honorary secretary of the German Migraine and Headache Society. J. Hipp and X. Hamann are employees of TEVA\u00a0GmbH. T. Kraya is or was member of the following advisory Boards: Allergan, and speaker or member of the following speaker boards: Allergan, TEVA, Lilly, Hormosan. L. Neeb was member of the following advisory boards: TEVA, Lilly Novartis and Hormosan and speaker or member of the following speakers\u2019 boards: Lilly, TEVA, Novartis, Abbvie and Hormosan Pharma He received grant support for research from TEVA and Lilly. He served in the editorial boards of Journal of Headache and Pain and Frontiers in Neurology.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}